Home / Cannabis Based Medicine

Cannabis Based Medicine

Zynerba Announces Positive Data from its Phase 2 Study of its CBD Gel Zygel in Developmental and Epileptic Encephalopathies

DEVON, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced positive top line results from the open label Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of Zygel™ …

Read More »

GW Pharma Reports Positive Results from its Phase 3 Trial of Epidiolex in Patients with Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase …

Read More »

INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

PHOENIX, Jan. 09, 2019 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray. These results identified a dose that showed a …

Read More »

Insys Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) — Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, was generally well-tolerated—even at high doses—as an investigational treatment for refractory pediatric epilepsy, according to new clinical …

Read More »

Cannabics Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2018 /PRNewswire/ —  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today the results of its pilot study to test the efficacy of Cannabics capsules for the treatment of cancer anorexia-cachexia …

Read More »

DEA Reschedules GW Pharma’s Epidiolex (cannabidiol) Oral Solution to Schedule V

LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral …

Read More »

Arena’s Olorinab Demonstrates Positive Phase 2a Results in Patients with Abdominal Pain Associated with Crohn’s Disease

SAN DIEGO, Sept. 24, 2018 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq :ARNA ) today announced positive topline results from its Phase 2a trial of olorinab, an investigational, peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of gastrointestinal pain. Phase 2a Trial …

Read More »

FDA Approves GW’s Cannabis-Based Drug Epidiolex for the Treatment of Rare, Severe Forms of Epilepsy

London, UK, Carlsbad, CA, June 25, 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration …

Read More »

Kalytera Provides Update on its Cannabis-Based Therapy for Prevention and Treatment of GVHD

SAN FRANCISCO and TEL AVIV, Israel, June 21, 2018 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the “Company” or “Kalytera”) today provided an update on its lead clinical development program evaluating cannabidiol (“CBD”) for the prevention and treatment of acute graft versus host disease (“GVHD”). GVHD is a …

Read More »

Most Oncologists Have Discussed Medical Marijuana with Patients

Data from a new survey show that as many as 80% of oncologists have discussed medical marijuana use with their patients. According to the authors, this is the first nationally-representative survey to examine oncologists’ practices and beliefs on the subject since the implementation of state medical marijuana laws. The research …

Read More »